6411 BECKLEY ST STE 201 BALTIMORE, MD 21224 Get Directions
6411 BECKLEY ST STE 201 BALTIMORE, MD 21224 Get Directions
Company Overview
Profectus BioSciences, Inc. ("Profectus") is an innovative clinical stage vaccine company enabled by an experienced development team from big pharma and two proprietary platform technologies in-licensed from Wyeth Vaccines (now Pfizer, Inc.). Profectus is developing the next generation of vaccines for high value unaddressed targets in biodefense, infectious, and emerging diseases.
The two in-licensed platforms greatly enhance the immunogenicity of prophylactic and therapeutic vaccines. They consist of first-in-class vaccines vectored with vesiculoviruses such as vesicular stomatitis virus (VSV), and best-in-class pDNA vaccines enhanced by the co-administration of GENEVAX IL-12(TM) and delivery with electroporation. Depending on the disease target, the pDNA and vesiculovirus-vectored vaccines are used singly or in prime/boost combination.
Two NIAID contracts, initially totaling more than $65M,were novated from Wyeth to Profectus as part of the in-licensing transaction. These funds advanced the pDNA and vesiculovirus vector programs through phase 1 safety and immunogenicity testing, both individually and in prime/boost combination. Profectus' two lead programs, heavily supported by non-dilutive funding, consist of a VSV-vectored vaccine for single dose pre- and post-exposure protection against the Category A threat agents Ebola and Marburg viruses, and a prime/boost therapeutic HIV vaccine in clinical evaluation to address the HIV "Cure Agenda".
The company is currently located in Baltimore, MD and Tarrytown,NY
© Dun & Bradstreet, Inc. 2025. All rights reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.